Goldman Sachs Group Analysts Give Reckitt Benckiser Group (LON:RB) a GBX 7,200 Price Target

Goldman Sachs Group set a GBX 7,200 ($94.08) price target on Reckitt Benckiser Group (LON:RB) in a research note released on Thursday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. set a €33.40 ($38.84) price target on Siemens Healthineers and gave the stock a neutral rating in a research note on Thursday. Kepler Capital Markets set a €14.00 ($16.28) price target on alstria office REIT and gave the stock a neutral rating in a research note on Tuesday, May 7th. HSBC set a $46.00 price target on Aqua America and gave the stock a buy rating in a research note on Friday, June 28th. Bryan, Garnier & Co cut their price target on GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a neutral rating for the company in a research note on Thursday, May 2nd. Finally, Deutsche Bank reiterated a hold rating and set a GBX 1,775 ($23.19) price target on shares of in a research note on Wednesday, June 26th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of GBX 7,211.11 ($94.23).

RB stock opened at GBX 6,595 ($86.18) on Thursday. The company has a debt-to-equity ratio of 80.49, a current ratio of 0.65 and a quick ratio of 0.47. The company has a market cap of $46.76 billion and a P/E ratio of 21.64. Reckitt Benckiser Group has a fifty-two week low of GBX 5,559 ($72.64) and a fifty-two week high of GBX 7,174 ($93.74). The business’s fifty day moving average price is GBX 6,384.22.



In other Reckitt Benckiser Group news, insider Adrian Nevil Hennah sold 13,701 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of GBX 6,143 ($80.27), for a total value of £841,652.43 ($1,099,767.97). Also, insider Andrew R. J. Bonfield purchased 146 shares of the stock in a transaction on Tuesday, May 21st. The stock was acquired at an average cost of GBX 6,290 ($82.19) per share, for a total transaction of £9,183.40 ($11,999.74).

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.

Featured Story: What is Liquidity?

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.